Skip to main content
RDGL
OTC Industrial Applications And Services

Vivos Q2 10-Q: Going Concern Warning, Material Weakness, and FDA IDE Approval

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Industrial
Sentiment info
Negative
Importance info
8
Price
$0.055
Mkt Cap
$27.016M
52W Low
$0.043
52W High
$0.144
52W Position info
29% above low
Off High info
62% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

RDGL sits 29% above its 52-week low of $0.043.

Summary

Vivos Inc.'s Q2 2026 10-Q reveals a going concern warning, a material weakness in internal controls, and a $2.0 million net loss, offset by FDA IDE approval for its RadioGel human therapy.


Key Events · Earnings and Guidance · RDGL

  • Going Concern Warning

    Cash of $2.34 million is insufficient to cover fixed and variable obligations; company requires approximately $3 million annually to maintain operations.

  • Material Weakness in Controls

    Disclosure controls and procedures were ineffective due to a material weakness related to proper segregation of duties.

  • FDA IDE Approval

    Received FDA approval in July 2026 for an Early Feasibility Investigational Device Exemption, enabling first-in-human study of RadioGel at Mayo Clinic for non-resectable papillary thyroid carcinoma.

  • Regulation A+ Offering

    Raised $2,203,800 in March/April 2026 through sale of 27.2 million shares and 27.8 million warrants.


Analysis · RDGL · Industrial Applications And Services

Vivos Inc. reported a net loss of $2.0 million for the first half of 2026 and disclosed that its cash position is insufficient to support operations, raising substantial doubt about its ability to continue as a going concern. The company also disclosed a material weakness in internal controls due to lack of segregation of duties. On the positive side, the FDA approved an Investigational Device Exemption in July 2026, enabling the first-in-human study of RadioGel at Mayo Clinic. The company raised $2.2 million in March/April 2026 through a Regulation A+ offering, but requires approximately $3 million annually to maintain operations.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RDGL was trading at $0.05 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $27M. The 52-week trading range was $0.04 to $0.14. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RDGL - Latest Insights

RDGL
Nov 12, 2026, 4:25 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.044
Real-time Price: $0.041 info
Change: -$0.0030 (-7%) info
Market Cap: $20.284M info
RDGL
Nov 09, 2026, 4:31 PM EST
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $0.0428
Real-time Price: $0.041 info
Change: -$0.0018 (-4%) info
Market Cap: $20.284M info
RDGL
Nov 05, 2026, 8:54 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.042
Real-time Price: $0.041 info
Change: -$0.0010 (-2%) info
Market Cap: $20.284M info
RDGL
Oct 08, 2026, 4:46 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.045885
Real-time Price: $0.041 info
Change: -$0.004885 (-11%) info
Market Cap: $20.284M info
RDGL
Oct 05, 2026, 5:26 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.0431
Real-time Price: $0.041 info
Change: -$0.0021 (-5%) info
Market Cap: $20.284M info